Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Excyte Biopharma Ltd
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).
This description comes directly from the study's public registry record.
Jie Jin, MD · +86-0571-87236898 · jiej0503@163.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| The First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Affiliated Zhongshan Hospital of Dalian University | Dalian, Liaoning, China | Recruiting |
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| The Second Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06580301